A B s T R A C T To define the pathophysiologic mechanisms of cold agglutinin disease, we investigated a human model of this syndrome in normal volunteers and in patients with diminished levels of serum complement. Subjects received intravenous injections of autologous, chromated (mCr) erythrocytes which had been exposed in vitro to purified cold agglutinin preparations and to fresh autologous serum (as a source of complement). In vitro tests confirmed that such cells were coated with activated complement components (C3b), but not with immunoglobulin.
A B s T R A C T To define the pathophysiologic mechanisms of cold agglutinin disease, we investigated a human model of this syndrome in normal volunteers and in patients with diminished levels of serum complement. Subjects received intravenous injections of autologous, chromated (mCr) erythrocytes which had been exposed in vitro to purified cold agglutinin preparations and to fresh autologous serum (as a source of complement). In vitro tests confirmed that such cells were coated with activated complement components (C3b), but not with immunoglobulin.
Studies of erythrocyte clearance and simultaneous organ scanning showed that erythrocytes sensitized with low levels of cold agglutinin primarily undergo reticuloendothelial sequestration by the liver rather than intravascular hemolysis. After the initial sequestration of C3b-coated erythrocytes, a fraction of the cells are released back into the circulation and survive nornmally thereafter. Both phenomena are dose dependent and closely follow the sequestration and release pattern observed with IgM isoagglutinin sensitization.
Experiments that used heated autologous serum as a source of C3 inactivator demonstrated that functionally intact C3b is required for hepatic sequestration. Erythrocytes coated with C3d were not cleared from the circulation. In vitro assays that used human macrophage monolayers suggested that the intrahepatic conversion of C3b to C3d is responsible for the release of sensitized erythrocytes back into the circulation.
The clearance of cold agglutinin-sensitized erythrocytes was compared to the clearance mediated by IgM isoagglutinin. We found that the rate of complement Presented in part at the National Meeting, American Federation for Clinical Research, Atlantic City, N. J., May, 1975. Received for publicationt 7 April 1976 and in revised fo-rm 22 Junte 1976. fixation by an IgM antibody proceeds so rapidly in vivo that the time for complement activation is not a factor in limiting the rate of hepatic sequestration. The major limiting factor appears to be the rate of liver blood flow.
Maximal in vitro coating of erythrocytes with C3d conferred protection from further cold agglutinin sensitization but not from IgM isoagglutinin-mediated clearance. This suggests a mechanism for the resistance to lysis observed in cells obtained from patients with the cold agglutinin syndrome and confirms the marked dependence of the site of C3 attachment on the site of menmbrane localization of the sensitizing antibody. erythrocytes obtained from patients with cold agglutinin disease survive longer in these patients than do cells obtained from normal donors (4, 5) . Furthermore, in one patient transfused with erythrocytes exposed to cold agglutinin and complement in vitro, Lewis, et al. found an unusual clearance pattern with rapid erythrocyte clearance followed by a partial reappearance in the intravascular space (6) . Moreover, despite the fact that the circulating erythrocytes of such patients are heavily coated with C3, most patients have a rather mild hemolytic process and their erythrocytes are more resistant to in vitro lysis by cold agglutinin and complement than are erythrocytes from normal individuals (5, 7).
INTRODUCTION
By using both human and animal systems, our laboratory and others previously have investigated the role of IgM antibody and complement in the in vivo destruction of erythrocytes (8) (9) (10) . In those studies the complement-dependent nature of the phenomenon was verified as was the predominant -role of the liver in cell sequestration. It was shown that the cell bound C3b fragment is primarily responsible for IgM-mediated hepatic uptake and it was suggested that the sequestration and release pattern is a function of complement activation.
The experiments reported here examine the effects of complement activation on erythrocyte clearance in cold agglutinin disease and bring together in vitro and in vivo data to further delineate the mechanism of the cold agglutinin syndrome.
METHODS
Antibodies. The cold agglutinin antibody used throughout these studies was obtained from a patient with idiopathic cold agglutinin syndrome. The initial purification technique and subsequent characterization of the antibody ( Step) have been previously reported (11) . In addition, further purification was achieved by Sephadex G200 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) fractionation and by sucrose density centrifugation (9) . This material was free of hepatitis antigen as determined by radioimmunoassay (9), and was sterile, and pyrogen free. Functional activity of the cold agglutinin was assayed by a modification of the Cl fixation and transfer test (12) , involving Cl fixation at 16WC rather than at 37°C. An estimation of the number of C3 molecules bound to erythrocytes/bound molecule of this cold agglutinin has been previously published by Rosse et al. using a modification of the method of Borsos and Leonard (11) . Radioiodination of the cold agglutinin with I-125 was performed with a modification of the iodine monochloride method (13) .
The purification and characterization of the IgM isoagglutinin has been reported in detail elsewhere (9 Techniques for erythrocyte clearance and localization. Human erythrocytes were separated, chromium-51 radiolabeled, and sensitized with antibody using methods identical to those previously reported (9) . In the initial studies, dilutions of cold agglutinin were added to an equal volume of an erythrocyte suspension (3.3 X 108 cells/ml) and incubated with mixing for 15 min at 16°C. Without washing, an equal volume of autologous fresh serum as a source of complement was added to the mixture for an additional 15 min at 16°C. A further incubation at 37°C for 15 min was then carried out to complete complement activation before twice washing the cells in warmed (37°C) saline to allow the cold agglutinin to dissociate. Such cells had C3b on their surface as shown by a positive immune adherence reaction and by direct agglutination by antibody to C3b (14) . Approximately 10 ml of a suspension of 3.3 X 107 cells/ml was then administered intravenously into the subject. Survival and organ localization studies were performed as previously described (9) . In a second group of studies, cells (3.3 X 108/ml) with membrane-bound C3b were incubated for 30 min at 370C with an equal volume of the patient's own serum (heated at 56°C for 60 min and diluted in Veronal buffered saline). Incubation in such heated sera led to no further deposition of complement, but the C3 INA, which is stable at 56°C, converted the C3b to C3d, as verified by loss of immune adherence reactivity as well as by reactivity with monospecific antibody to C3d. The clearance and localization studies proceeded as above.
Itt vzitro studies. Human alveolar macrophages were obtained from volunteers and patients by lavage of the lingual lobe through a fiber optic bronchoscope. Details of this technique as well as characterization, quantitation, and cellular analysis of the alveolar fluid have been published elsewhere (15) . Alveolar macrophage monolayers were prepared by adding approximately 1.5 X 106 macrophages in Hank's buffered salt solution to 1 X 1 cm Lab Tek chambers (Lab Tek Products, Naperville, Ill.) and were incubated in 5% C02 at 37°C for 1 h before use. The resulting macrophage monolayers were overlaid with the erythrocyte preparations (see Results), and the percentage of rosettes was determined as previously reported (14) .
Immune adherence assays were performed as previously described (16) .
RESULTS
In vivo clearance in normal volunteers. Approximately 10 ml of autologous erythrocytes (3.3 X 107 cells/ml) coated in vitro with autologous serum complements components were injected intravenously into each volunteer. Cells prepared in the manner described above were not agglutinated and were Coombs negative with anti-immunoglobulin antibody. However, C3 could be detected with appropriate Coombs reagents. The amount of C3 fixation with this preparation varied directly with the amounts of cold agglutinin. Previous studies with this antibody showed that 100 cell bound molecules of cold agglutinin fixed approximately 700 molecules of C3 (11) . We also determined the number of bound cold agglutinin molecules by both the Cl fixation and transfer test and by the uptake of "2I antibody (approximately one Cl fixing site per 10 molecules of bound cold agglutinin). This is in agreement with previously published results using this antibody (11) . Even at relatively low levels of complement coating, the radiolabeled erythrocytes were rapidly removed from the circulation during the first 10 min (Fig. 1) . The time required for sequestration of one-half of the labeled erythrocytes was approximately 3i min, with greater than 40% of the cells removed from the intravascular space during the first 6 min. There was a concomitant rise in radioactivity over the liver (Fig. 2) . This rapid rate of removal suggests that hepatic blood flow is the limiting factor in sequestration. Shortly thereafter, and for at least the next 24 h, there was a progressive release of the sequestered erythrocytes into the circulation and a corresponding decrease in activity over the liver.
As the concentration of sensitizing antibody increased, and hence the amount of complement fixation increased, the degree of erythrocyte sequestration was altered directly. Thus, the greater the initial percentage of sequestration, the smaller the percentage of cells which eventually reappeared in the circulation (Fig. 3) . With 75, 150, and 300 Cl sites per erythrocyte, 12, 39, and 67% of the injected cells were initially sequestered in the liver, and approximately 95, 79, and 50% respectively were returned to the circulation by 24 h. After 24 h, cells no longer were released into the intravascular space; the remaining cells survived with a half-life of 59 days. The kinetics of sequestration and release using cold agglutinin sensitization and complement coating in vitro were indistinguishable from results obtained when erythrocytes were sensitized in vitro with IgM isoagglutinin and subsequent complement fixation was allowed to proceed in vivo (Fig. 4) . Thus, the time required for sensitized cells to interact with complement in vivo did not alter the kinetics.
To prepare erythrocytes coated with C3d, C3b erythrocytes prepared as described above were subsequently incubated at 37°C for 30 min with heated autologous serum (56°C for 60 min), which served as a source of C3 INA. Fig. 5 compares the sequestration and release pattern of erythrocytes coated with C3b and those coated with C3d, as verified by using monospecific In an effort to maximally coat erythrocytes with C3d, cell suspensions were sensitized initially with cold agglutinin and then twice cycled through the complement fixation procedure by repeated exposure to fresh serum first at 160C then at 37°C followed by washing and incubation with a source of C3 INA. Further exposure of these cells to cold agglutinin and fresh serum did not lead to additional fixation of C3b as evidenced by the failure of the cells to mediate an immune adherence reaction or to exhibit accelerated erythrocyte clearance (Fig. 6) . Agglutination of such cells by antibody to C3d confirmed its presence on the erythrocyte surface.
In a parallel experiment, erythrocytes maximally coated with C3d as above were subsequently exposed to IgM isoagglutinin instead of to cold agglutinin and fresh serum. Such cells were capable of further C3 fixation as evidenced by the typical sequestration and release pattern following intravenous administration (Fig. 6) .
In vitro studies. Immune adherence studies that used microtiter techniques described previously were performed by using erythrocytes sensitized with 150 Cl fixing sites of cold agglutinin per cell. The results In parallel studies, cells prepared by these techniques were overlayed on monolayers of human alveolar macrophages. The data (Table I) reaffirm the concept that erythrocytes coated with C3b but not with C3d are capable of rosetting with macrophages and that cells coated maximally with the C3d component do not form rosettes despite reexposure to the cold agglutinin and a fresh complement source.
In vivo clecarance in complement deficient patients.
Clearance studies in patients with hereditary angioedema were performed identically to those in normal volunteers (Table II) Abbrevtations used: A, antibody (cold agglutinin); C, whole complement source; C3INA, C3 inactivator; E, erythrocyte; IgM, IgM isoagglutinin.
* Direct Coombs test using monospecific antisera.
t Visually scored in microtiter assay (16) . § Percentage of macrophages which bind three or more erythrocytes.
Percentage of administered erythrocytes cleared from the circulation by 20 min.
sufficient complement is activated at the erythrocyte surface to achieve hepatic sequestration, the cells undergo normal survival; at no dose of complement, could we demonstrate preferential splenic sequestration. The hepatic clearance of IgM isoagglutinin-coated cells was first established by the early studies of Jandl et al. (19) and Mollison (20) . They suggested that entrapment by the liver was caused by extensive erythrocyte membrane damage. Evans and co-workers (4) were also able to demonstrate the hepatic sequestration of transfused cells in patients with cold agglutinin syndrome despite the apparent normal survival of a portion of the cells which remained in the circulation. Our data suggest that complement (C3b) is essential for hepatic sequestration and confirm that the macrophage receptor for C3b is capable of binding these sensitized erythrocytes. Thus, the hepatic -sequestration of cold agglutinin sensitized cells is more likely a function of erythrocyte binding at specific hepatic macrophage receptor sites for C3b rather than nonspecific membrane damage. In support of this, Brown and his colleagues (10) were able to show that cold agglutinins injected into rabbits produced rosetting on hepatic macrophages rather than causing cellular damage per se. Additional evidence substantiating the importance of complement in IgM mediated clearance in man comes from the findings that IgM isoagglutinin coated cells are not cleared in patients deficient in C4 and C2 (9) , and that receptors for homologous IgM have not been identified on human alveolar macrophages (14) , or on peripheral blood monocytes (14, 21) .
A compatible, though not mutually exclusive hypothesis has been proposed, whereby C3b reduces erythrocyte deformability (22) . Since cytes are cleared by the spleen as are erythrocytes with defects in deformability (23) . Nevertheless, splenic sequestration does not occur irrespective of the level of erythrocyte sensitization. Moreover, the concept of partially reversible deformability is not entirely consistent with the finding that cells from cold agglutinin patients survive longer in patients with the disease than do normal erythrocytes, unless the decrease in deformability is not functionally significant. A possible in vitro correlate of the hepatic release phenomenon can be demonstrated by the conversion of the cell-bound C3b to C3d. This is achieved by exposing erythrocytes with functionally bound C3b to a source of the C3 INA (heated ;serum), thereby cleaving C3b to C3d. When administered intravenously, C3d coated erythrocytes are not cleared despite the presence of C3d receptors on macrophages and lymphocytes. We have previously suggested that such C3d is either not available to the macrophage receptors or is not in the proper biochemical or configurational form to mediate clearance (14) . These data are in accord with that hypothesis. It has been reported that the circulating erythrocytes of patients with cold agglutinin syndrome are coated with C3d, but not C3b (5). Thus, the presence of C3d may preclude the sufficiently rapid fixation of further C3 (4, 5) or cold agglutinin (24) , or simply reduce the amount of C3b below the threshold of receptor recognition. This too, would explain the observation of Evans et al. that previously sensitized erythrocytes survive longer than normal donor erythrocytes when injected into patients with active cold agglutinin syndrome (4) .
Our human in vivo data demonstrate the phenomenon of hepatic sequestration and release. The findings are similar to those in a patient reported by Lewis, et al. (6) and those reported in a rabbit model by Brown et al. (10) . The time course of cellular sequestration and release is identical whether antibody-free, C3-coated erythrocytes, or complement-free, IgM isoagglutinincoated erythrocytes are administered intravenously. This suggests that in vivo complement fixation of the IgM coated cells proceeds so rapidly that it does not influence the rate of sequestration by the liver. Clearance appears to depend primarily upon the rate of hepatic blood flow. This is further supported by the finding that the rate of clearance of C3b-coated erythrocytes approximates that reported for other liver blood flow dependent colloid particulate materials (25, 26) . More- over, the shape of the sequestration and release curve does not reflect continued complement activation after the cells are injected (since the cells were washed free of antibody), but rather depends upon the interaction of cell bound complement and serum factors, presumably C3 INA. Recently, Logue et al. (17) established the importance of the rate and the amount of C3 fixation in the pathogenesis of the hemolytic state. Our data involving repeated complement exposure confirm and extend the premise relating the rate of complement fixation to the severity of the diseases. In fact, prolonged exposure to C3 and its inactivator, which is maximized in the in vitro model, confers "protection" on erythrocytes against further complement deposition. This protection by complement explains both the enhanced survival of in vivo coated cells when reinjected into patients with this syndrome (4, 5) as well as the observation of reduced susceptibility to in vitro lysis when compared with normal controls (5, 7) . In fact, by using this particular cold agglutinin, enough C3d could be deposited so as to essentially prevent the further deposition of complement components. The finding that cold agglutinin antibodies are directed against only a portion of the erythrocyte antigen (27) may explain the variability of this protection phenomenon (11) .
The data presented here on double-sensitization with a second IgM isoagglutinin also establish that the deposition of inactivated complement components at the I sites does not precludle subsequent fixation of complement at other more ubiquitous blood group antigen sites. The finding of a limited site for C3 binding by cold agglutinin is of importance in understanding the mechanisms of C3 activation. It has been shown that activation of C3 leads to the formation of an evanescent, fairly nonspecific binding site which allows the C3b fragment to attach to molecular species in the general area of activation (28) . Furthermore, the active C3 fragment, unlike the active C5 cleavage product, cannot traverse large distances before binding (i.e., C3b unlike C5b does not transfer from sensitized to unsensitized sheep erythrocytes in a mixture of sensitized and unsensitized cells and complement) (29) . These experiments in a human system confirm the limited extent of membrane fixation of C3b on individual cells and demonstrate the marked dependence of C3 fixation on the membrane localization of the sensitizing antibody.
Thus, these studies lead to a further understanding of the clinical manifestations of the cold agglutinin syndrome and to the pathophysiologic role of complement in the development of the disease. As suggested by Jandl et al. (19) 
